메뉴 건너뛰기




Volumn 73, Issue 5, 2013, Pages 512-521

Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer

Author keywords

castration resistant prostate cancer; docetaxel resistance; IL 6; NF B

Indexed keywords

DOCETAXEL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; PREDNISONE; SYNAPTOTAGMIN I;

EID: 84875220862     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22591     Document Type: Article
Times cited : (52)

References (37)
  • 7
    • 25444514064 scopus 로고    scopus 로고
    • Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells
    • Zerbini LF, Wang Y, Correa RG, Cho JY, Libermann TA,. Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. Cell Cycle 2005; 4: 1247-1253.
    • (2005) Cell Cycle , vol.4 , pp. 1247-1253
    • Zerbini, L.F.1    Wang, Y.2    Correa, R.G.3    Cho, J.Y.4    Libermann, T.A.5
  • 8
    • 69749117003 scopus 로고    scopus 로고
    • New insights into the role of interleukin-6 in human prostate cancer
    • Culig Z,. New insights into the role of interleukin-6 in human prostate cancer. J Urol 2009; 182: 1255-1256.
    • (2009) J Urol , vol.182 , pp. 1255-1256
    • Culig, Z.1
  • 10
    • 46749085910 scopus 로고    scopus 로고
    • Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma
    • Cavarretta IT, Neuwirt H, Zaki MH, Steiner H, Hobisch A, Nemeth JA, Culig Z,. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv Exp Med Biol 2008; 617: 547-555.
    • (2008) Adv Exp Med Biol , vol.617 , pp. 547-555
    • Cavarretta, I.T.1    Neuwirt, H.2    Zaki, M.H.3    Steiner, H.4    Hobisch, A.5    Nemeth, J.A.6    Culig, Z.7
  • 12
    • 3242798367 scopus 로고    scopus 로고
    • NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenon?
    • Suh J, Rabson AB,. NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenon? J Cell Biochem 2004; 91: 100-117.
    • (2004) J Cell Biochem , vol.91 , pp. 100-117
    • Suh, J.1    Rabson, A.B.2
  • 14
    • 51049109691 scopus 로고    scopus 로고
    • The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells
    • Zemskova M, Sahakian E, Bashkirova S, Lilly M,. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem 2008; 283: 20635-20644.
    • (2008) J Biol Chem , vol.283 , pp. 20635-20644
    • Zemskova, M.1    Sahakian, E.2    Bashkirova, S.3    Lilly, M.4
  • 17
    • 33745298519 scopus 로고    scopus 로고
    • Nuclear factor-kappaB in cancer development and progression
    • Karin M,. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436.
    • (2006) Nature , vol.441 , pp. 431-436
    • Karin, M.1
  • 18
    • 0038036872 scopus 로고    scopus 로고
    • Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer
    • Zerbini LF, Wang Y, Cho JY, Libermann TA,. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003; 63: 2206-2215.
    • (2003) Cancer Res , vol.63 , pp. 2206-2215
    • Zerbini, L.F.1    Wang, Y.2    Cho, J.Y.3    Libermann, T.A.4
  • 22
    • 24044482568 scopus 로고    scopus 로고
    • Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis
    • Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D,. Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 2005; 44: 51-59.
    • (2005) Mol Carcinog , vol.44 , pp. 51-59
    • Venkatraman, M.1    Anto, R.J.2    Nair, A.3    Varghese, M.4    Karunagaran, D.5
  • 23
    • 73849090217 scopus 로고    scopus 로고
    • IKK/NF-kappaB and STAT3 pathways: Central signalling hubs in inflammation-mediated tumour promotion and metastasis
    • Bollrath J, Greten FR,. IKK/NF-kappaB and STAT3 pathways: Central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009; 10: 1314-1319.
    • (2009) EMBO Rep , vol.10 , pp. 1314-1319
    • Bollrath, J.1    Greten, F.R.2
  • 24
    • 68849108869 scopus 로고    scopus 로고
    • Inflammation and cancer: How friendly is the relationship for cancer patients?
    • Aggarwal BB, Gehlot P,. Inflammation and cancer: How friendly is the relationship for cancer patients? Curr Opin Pharmacol 2009; 9: 351-369.
    • (2009) Curr Opin Pharmacol , vol.9 , pp. 351-369
    • Aggarwal, B.B.1    Gehlot, P.2
  • 26
    • 2942627100 scopus 로고    scopus 로고
    • Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells
    • Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK, Kuo ML,. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 2004; 60: 120-129.
    • (2004) Prostate , vol.60 , pp. 120-129
    • Pu, Y.S.1    Hour, T.C.2    Chuang, S.E.3    Cheng, A.L.4    Lai, M.K.5    Kuo, M.L.6
  • 28
    • 66449085018 scopus 로고    scopus 로고
    • Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2
    • Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC,. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther 2009; 8: 665-671.
    • (2009) Mol Cancer Ther , vol.8 , pp. 665-671
    • Feng, S.1    Tang, Q.2    Sun, M.3    Chun, J.Y.4    Evans, C.P.5    Gao, A.C.6
  • 29
    • 77449146168 scopus 로고    scopus 로고
    • Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
    • Santer FR, Malinowska K, Culig Z, Cavarretta IT,. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 2010; 17: 241-253.
    • (2010) Endocr Relat Cancer , vol.17 , pp. 241-253
    • Santer, F.R.1    Malinowska, K.2    Culig, Z.3    Cavarretta, I.T.4
  • 30
    • 0028880675 scopus 로고
    • Endogenous interleukin 6 is a resistance factor for cis- diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines
    • Borsellino N, Belldegrun A, Bonavida B,. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995; 55: 4633-4639.
    • (1995) Cancer Res , vol.55 , pp. 4633-4639
    • Borsellino, N.1    Belldegrun, A.2    Bonavida, B.3
  • 31
    • 23044498269 scopus 로고    scopus 로고
    • Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells
    • Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH,. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005; 65: 6934-6942.
    • (2005) Cancer Res , vol.65 , pp. 6934-6942
    • Li, Y.1    Ahmed, F.2    Ali, S.3    Philip, P.A.4    Kucuk, O.5    Sarkar, F.H.6
  • 32
    • 0036838869 scopus 로고    scopus 로고
    • Multiple transcription factors regulating the IL-6 gene are activated by cAMP in cultured Caco-2 cells
    • Hershko DD, Robb BW, Luo G, Hasselgren PO,. Multiple transcription factors regulating the IL-6 gene are activated by cAMP in cultured Caco-2 cells. Am J Physiol Regul Integr Comp Physiol 2002; 283: R1140-R1148.
    • (2002) Am J Physiol Regul Integr Comp Physiol , vol.283
    • Hershko, D.D.1    Robb, B.W.2    Luo, G.3    Hasselgren, P.O.4
  • 33
    • 0033527448 scopus 로고    scopus 로고
    • The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter
    • Vanden BW, De BK, Boone E, Plaisance S, Haegeman G,. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 1999; 274: 32091-32098.
    • (1999) J Biol Chem , vol.274 , pp. 32091-32098
    • Vanden, B.W.1    De, B.K.2    Boone, E.3    Plaisance, S.4    Haegeman, G.5
  • 34
    • 0025720735 scopus 로고
    • The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation
    • Angel P, Karin M,. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-157.
    • (1991) Biochim Biophys Acta , vol.1072 , pp. 129-157
    • Angel, P.1    Karin, M.2
  • 35
    • 16344365813 scopus 로고    scopus 로고
    • The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 9480
    • George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW,. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 9480. Clin Cancer Res 2005; 11: 1815-1820.
    • (2005) Clin Cancer Res , vol.11 , pp. 1815-1820
    • George, D.J.1    Halabi, S.2    Shepard, T.F.3    Sanford, B.4    Vogelzang, N.J.5    Small, E.J.6    Kantoff, P.W.7
  • 36
    • 35948969806 scopus 로고    scopus 로고
    • A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    • Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI,. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. J Urol 2007; 178: 2378-2383.
    • (2007) J Urol , vol.178 , pp. 2378-2383
    • Morris, M.J.1    Kelly, W.K.2    Slovin, S.3    Ryan, C.4    Eicher, C.5    Heller, G.6    Scher, H.I.7
  • 37
    • 77953091816 scopus 로고    scopus 로고
    • Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer
    • Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, Van VP Jr, Quinn DI, Vogelzang NJ, Thompson IM Jr, Hussain MH,. Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010; 16: 3028-3034.
    • (2010) Clin Cancer Res , vol.16 , pp. 3028-3034
    • Dorff, T.B.1    Goldman, B.2    Pinski, J.K.3    MacK, P.C.4    Lara, Jr.P.N.5    Van, Jr.V.P.6    Quinn, D.I.7    Vogelzang, N.J.8    Thompson, Jr.I.M.9    Hussain, M.H.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.